Fusen Pharmaceutical Company Limited (1652.HK) Comparison with companies in other sectors?

Fusen Pharmaceutical Company Limited has a share price of 739.30M. You can analyze Fusen Pharmaceutical Company Limited (1652.HK) competitors across different market sectors through stock heatmaps.

What are 1652.HK's NET and operating margins?

Fusen Pharmaceutical Company Limited (1652.HK) operating margin is around -0.21, and net profit margin is approximately -0.58 as of the latest reports.

In what way does 1652.HK's earnings per share (EPS) trend reflect its financial momentum?

Fusen Pharmaceutical Company Limited (1652.HK) EPS is -0.28 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Fusen Pharmaceutical Company Limited is -1.14, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Fusen Pharmaceutical Company Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Fusen Pharmaceutical Company Limited like P/E which is -1.15, P/B which is 0.59, and PEG which is 0.04. Compare them with sector averages to evaluate if the stock is priced fairly.

Fusen Pharmaceutical Company Limited

1652.HK•HKSE

Healthcare

Drug Manufacturers - Specialty & Generic

HK$0.32

HK$-0.04(-11.11%)

Fusen Pharmaceutical Company Limited (1652.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.28

P/E Ratio

-1.14

ROE

-0.42%

Net Margin

-0.58%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$236.58M

Shares OutstandingTotal number of shares issued

$739.30M

Book Value/ShareNet worth per share

$0.50

Revenue/ShareAnnual revenue per share

$0.44

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.28

Net MarginNet income as percentage of revenue

-57.90%

Operating MarginOperating income as percentage of revenue

-20.71%

ROEReturn on shareholders' equity

-42.42%

ROAReturn on total assets

-15.25%

ROCEReturn on capital employed

-14.50%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.07

Cash/ShareCash and equivalents per share

$0.03

FCF YieldFree cash flow as percentage of market cap

-24.06%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 1652.HKFinancial Ratios Analysis details for 1652.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 1652.HKSector Benchmarking details for 1652.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Fusen Pharmaceutical Company Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Fusen Pharmaceutical Company Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Fusen Pharmaceutical Company Limited's unique business strengths and challenges.

Key Financial Metrics for Fusen Pharmaceutical Company Limited

For Fusen Pharmaceutical Company Limited, essential financial indicators include EPS -0.28, PE -1.14, and ROE -0.42. These key ratios reveal insights into Fusen Pharmaceutical Company Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Fusen Pharmaceutical Company Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Fusen Pharmaceutical Company Limited

Metrics like Net Margin -57.90% and ROA -15.25% shed light on how well Fusen Pharmaceutical Company Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Fusen Pharmaceutical Company Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Fusen Pharmaceutical Company Limited

Using ratios such as P/B Ratio 0.59 and PEG Ratio 0.04, investors can assess whether Fusen Pharmaceutical Company Limited is appropriately valued based on its financials and growth potential. These figures, combined with Fusen Pharmaceutical Company Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Fusen Pharmaceutical Company Limited

Financial health indicators, such as Debt/Equity Ratio 1.04 and Cash Flow $-0.07, provide a snapshot of Fusen Pharmaceutical Company Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Fusen Pharmaceutical Company Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Fusen Pharmaceutical Company Limited

Investing in Fusen Pharmaceutical Company Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Fusen Pharmaceutical Company Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;